TLSI
TriSalus Life Sciences, Inc.
Medical - Devices
Market Cap$142M
5Y Perf.-55.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TLSI vs IRTC
Revenue, margins, valuation, and 5-year total return — side by side.
IRTC
iRhythm Technologies, Inc.
Medical - Devices
Market Cap$3.87B
5Y Perf.-26.8%
TLSI vs IRTC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TLSI | IRTC |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $142M | $3.87B |
| Revenue (TTM) | $45M | $788M |
| Net Income (TTM) | $-39M | $-28M |
| Gross Margin | 84.6% | 71.0% |
| Operating Margin | -59.7% | -3.3% |
| Total Debt | $34M | $731M |
| Cash & Equiv. | $20M | $236M |
TLSI vs IRTC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TLSI
IRTC
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| TriSalus Life Scien… (TLSI) | 100 | 44.3 | -55.7% |
| iRhythm Technologie… (IRTC) | 100 | 73.2 | -26.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TLSI vs IRTC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IRTC leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. TriSalus Life Sciences, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TLSI
TriSalus Life Sciences, Inc.
The Growth Play
TLSI is the clearest fit if your priority is growth exposure.
- Rev growth 53.4%, EPS growth -47.2%, 3Y rev CAGR 53.9%
- 53.4% revenue growth vs IRTC's 26.2%
- -11.5% vs IRTC's -12.9%
Best for: growth exposure
IRTC
iRhythm Technologies, Inc.
The Income Pick
IRTC carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.93
- 351.8% 10Y total return vs TLSI's -56.7%
- Lower volatility, beta 0.93, current ratio 4.63x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TLSI | 53.4% revenue growth vs IRTC's 26.2% |
| Quality / Margins | IRTC | -3.5% margin vs TLSI's -86.9% |
| Stability / Safety | IRTC | Beta 0.93 vs TLSI's 1.36 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TLSI | -11.5% vs IRTC's -12.9% |
| Efficiency (ROA) | IRTC | -2.8% ROA vs TLSI's -110.7% |
TLSI vs IRTC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
TLSI vs IRTC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIRTCLAGGINGTLSI
TLSITriSalus Life Science…
0leads
IRTCiRhythm Technologies,…
3leads
6 Total Categories
CATEGORYLEADERvs TLSIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IRTC4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IRTC4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
IRTC4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IRTC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IRTC is the larger business by revenue, generating $788M annually — 17.4x TLSI's $45M. IRTC is the more profitable business, keeping -3.5% of every revenue dollar as net income compared to TLSI's -86.9%. On growth, TLSI holds the edge at +59.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TLSITriSalus Life Sci… | IRTCiRhythm Technolog… |
|---|---|---|
| RevenueTrailing 12 months | $45M | $788M |
| EBITDAEarnings before interest/tax | -$26M | -$6M |
| Net IncomeAfter-tax profit | -$39M | -$28M |
| Free Cash FlowCash after capex | -$19M | $19M |
| Gross MarginGross profit ÷ Revenue | +84.6% | +71.0% |
| Operating MarginEBIT ÷ Revenue | -59.7% | -3.3% |
| Net MarginNet income ÷ Revenue | -86.9% | -3.5% |
| FCF MarginFCF ÷ Revenue | -41.9% | +2.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +59.8% | +25.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +48.8% | +55.7% |
IRTC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — TLSI and IRTC each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TLSITriSalus Life Sci… | IRTCiRhythm Technolog… |
|---|---|---|
| Market CapShares × price | $142M | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $156M | $4.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.47x | -84.68x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.15x | 5.18x |
| Price / BookPrice ÷ Book value/share | — | 24.66x |
| Price / FCFMarket cap ÷ FCF | — | 112.01x |
Evenly matched — TLSI and IRTC each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IRTC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), IRTC scores 6/9 vs TLSI's 4/9, reflecting solid financial health.
| Metric | TLSITriSalus Life Sci… | IRTCiRhythm Technolog… |
|---|---|---|
| ROE (TTM)Return on equity | — | -20.6% |
| ROA (TTM)Return on assets | -110.7% | -2.8% |
| ROICReturn on invested capital | — | -5.2% |
| ROCEReturn on capital employed | -143.4% | -4.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 4.79x |
| Net DebtTotal debt minus cash | $14M | $495M |
| Cash & Equiv.Liquid assets | $20M | $236M |
| Total DebtShort + long-term debt | $34M | $731M |
| Interest CoverageEBIT ÷ Interest expense | -9.61x | -1.48x |
IRTC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
IRTC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IRTC five years ago would be worth $15,710 today (with dividends reinvested), compared to $4,671 for TLSI. Over the past 12 months, TLSI leads with a -11.5% total return vs IRTC's -12.9%. The 3-year compound annual growth rate (CAGR) favors IRTC at -2.6% vs TLSI's -23.9% — a key indicator of consistent wealth creation.
| Metric | TLSITriSalus Life Sci… | IRTCiRhythm Technolog… |
|---|---|---|
| YTD ReturnYear-to-date | -25.4% | -32.8% |
| 1-Year ReturnPast 12 months | -11.5% | -12.9% |
| 3-Year ReturnCumulative with dividends | -55.9% | -7.7% |
| 5-Year ReturnCumulative with dividends | -53.3% | +57.1% |
| 10-Year ReturnCumulative with dividends | -56.7% | +351.8% |
| CAGR (3Y)Annualised 3-year return | -23.9% | -2.6% |
IRTC leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TLSI and IRTC each lead in 1 of 2 comparable metrics.
Risk & Volatility
IRTC is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than TLSI's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | TLSITriSalus Life Sci… | IRTCiRhythm Technolog… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.36x | 0.93x |
| 52-Week HighHighest price in past year | $7.95 | $212.00 |
| 52-Week LowLowest price in past year | $3.42 | $112.31 |
| % of 52W HighCurrent price vs 52-week peak | +57.2% | +55.5% |
| RSI (14)Momentum oscillator 0–100 | 57.8 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 167K | 521K |
Evenly matched — TLSI and IRTC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TLSI as "Buy" and IRTC as "Buy". Consensus price targets imply 130.8% upside for TLSI (target: $11) vs 64.5% for IRTC (target: $194).
| Metric | TLSITriSalus Life Sci… | IRTCiRhythm Technolog… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.50 | $193.67 |
| # AnalystsCovering analysts | 2 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IRTC leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OveralliRhythm Technologies, Inc. (IRTC)Leads 3 of 6 categories
Loading custom metrics...
TLSI vs IRTC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TLSI or IRTC a better buy right now?
For growth investors, TriSalus Life Sciences, Inc.
(TLSI) is the stronger pick with 53. 4% revenue growth year-over-year, versus 26. 2% for iRhythm Technologies, Inc. (IRTC). Analysts rate TriSalus Life Sciences, Inc. (TLSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TLSI or IRTC?
Over the past 5 years, iRhythm Technologies, Inc.
(IRTC) delivered a total return of +57. 1%, compared to -53. 3% for TriSalus Life Sciences, Inc. (TLSI). Over 10 years, the gap is even starker: IRTC returned +351. 8% versus TLSI's -56. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TLSI or IRTC?
By beta (market sensitivity over 5 years), iRhythm Technologies, Inc.
(IRTC) is the lower-risk stock at 0. 93β versus TriSalus Life Sciences, Inc. 's 1. 36β — meaning TLSI is approximately 46% more volatile than IRTC relative to the S&P 500.
04Which is growing faster — TLSI or IRTC?
By revenue growth (latest reported year), TriSalus Life Sciences, Inc.
(TLSI) is pulling ahead at 53. 4% versus 26. 2% for iRhythm Technologies, Inc. (IRTC). On earnings-per-share growth, the picture is similar: iRhythm Technologies, Inc. grew EPS 61. 7% year-over-year, compared to -47. 2% for TriSalus Life Sciences, Inc.. Over a 3-year CAGR, TLSI leads at 53. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TLSI or IRTC?
iRhythm Technologies, Inc.
(IRTC) is the more profitable company, earning -6. 0% net margin versus -154. 3% for TriSalus Life Sciences, Inc. — meaning it keeps -6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRTC leads at -4. 9% versus -59. 7% for TLSI. At the gross margin level — before operating expenses — TLSI leads at 84. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TLSI or IRTC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TLSI or IRTC better for a retirement portfolio?
For long-horizon retirement investors, iRhythm Technologies, Inc.
(IRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), +351. 8% 10Y return). Both have compounded well over 10 years (IRTC: +351. 8%, TLSI: -56. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TLSI and IRTC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(TLSI: 59.8% · IRTC: 25.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.